Cognivue, Inc.

Cognivue manufactures FDA-cleared digital cognitive assessment devices for early detection of cognitive impairment. The company's proprietary adaptive psychophysics technology collects 130,000 data points per assessment, delivering self-administered computerized evaluations customized to each patient's visual and motor skills. The platform removes bias inherent in traditional cognitive assessment tools and provides standardized testing across diverse healthcare settings. Cognivue offers two primary product lines: Cognivue Clarity®, a 10-minute comprehensive assessment evaluating four cognitive domains (memory, executive function/attention, discrimination, visuospatial) plus two performance parameters; and Cognivue Thrive®, a 5-minute abbreviated screening tool assessing three cognitive domains (memory, visuospatial, executive function). Both devices are validated against gold-standard assessment tools such as Montreal Cognitive Assessment (MoCA) and St. Louis University Mental Status (SLUMS) examination, demonstrating superior test-retest reliability and high sensitivity for detecting mild cognitive impairment. The company markets its assessment platform to physicians, hearing healthcare providers, and pharmacies. Clinical data demonstrates Cognivue's effectiveness as an adjunctive tool for cognitive function evaluation in primary care, geriatric, audiology, and pharmacy settings. Cognivue also offers Cogniwell®, a patient-facing lifestyle program complementing clinical assessment. The devices are indicated as adjunctive tools and require licensed clinician interpretation; they do not function as standalone diagnostic instruments. Cognivue is headquartered in Victor, NY, and maintains FDA 510(k) clearance for its technology platform.